AstraZeneca set to showcase the latest in respiratory science at the 2018 European Respiratory Society (ERS) International Congress

At AstraZeneca, we aim to transform the treatment of respiratory disease with our growing portfolio of inhaled and biologics medicines, along with scientific research targeting the underlying causes of the diseases. We look forward to joining clinicians, researchers and scientists at the 2018 European Respiratory Society (ERS) International Congress to share the latest in respiratory science advancements. Follow us on Twitter and LinkedIn, and join the conversation using #ERSCongress.

Targeting the inaccessible: new drug modalities in lung disease

Anticalin® molecules are small engineered proteins mimicking monoclonal antibodies but with the advantage of direct delivery to the lung.

Targeting epithelial cytokines may prevent the release of pro-inflammatory cytokines by immune cells, which may result in the prevention of asthma exacerbations and improved asthma control.

Immunostimulatory oligonucleotides have the potential to correct imbalances in the immune system that are seen in many asthma sufferers.

Our aim is to modify and ultimately cure Respiratory disease. To get there, we need to be able to target any novel biology we uncover and address targets previously seen as inaccessible. This is where new, inhaled drug modalities will help us succeed.

Supporting changes in respiratory clinical care


How can AstraZeneca make a difference?

Hear more from the talent of AstraZeneca who contribute to our commitment to respiratory disease. Our 40-year heritage in respiratory science is just the beginning of our story.

Pushing the boundaries to deliver innovative solutions

AstraZeneca has taken the number one spot in IDEA Pharma’s Pharmaceutical Innovation Index – celebrating the most innovative companies in pharma. Hear more from the people who are leading in respiratory.

Maria Belvisi

Vice President and Head, RIA Innovative Medicines

Tom Keith-Roach

Therapy Area Vice President, Respiratory

Rene Van der Merwe

Vice President, Clinical Respiratory

Colin Reisner

Head, Respiratory Global Medicines, AstraZeneca and CEO of Pearl Therapeutics

Veeva ID: Z4-12941
Date of next review: September 2020